January 2009 in “Acta urologica Belgica” Finasteride effectively treats BPH by reducing prostate size and improving symptoms.
58 citations
,
March 2006 in “Current topics in medicinal chemistry” Dutasteride effectively treats benign prostatic hyperplasia and may reduce prostate cancer risk.
75 citations
,
January 2014 in “Korean Journal of Urology” 5α-reductase inhibitors can cause sexual problems, higher risk of aggressive prostate cancer, and depression.
February 2013 in “Americanae (AECID Library)” Finasteride may reduce prostate tumor cell invasion and spread.
5 citations
,
January 2014 in “Molecular Simulation” A new compound may treat benign prostatic hyperplasia better than finasteride.
86 citations
,
July 1993 in “Drugs” Finasteride treats enlarged prostate, shrinks it, improves urination, but may cause sexual dysfunction and isn't for women or children.
April 2026 in “The Journal of Urology” Low-dose finasteride may increase erectile dysfunction risk over time.
October 2025 in “Journal of the Endocrine Society” Finasteride lowers cholesterol but doesn't reduce heart-related events.
Finasteride, a medication, is being re-evaluated for its effects and uses.
186 citations
,
December 2011 in “Molecules” Three specific 4-azasteroid-2-oximes showed strong enzyme inhibition, but less than finasteride.
December 2023 in “Revista Urología Colombiana / Colombian Urology Journal” More research is needed to find effective treatments for sickle cell disease-related priapism.
7 citations
,
January 2013 in “European Urology” 5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.
11 citations
,
February 2016 in “Current Medicinal Chemistry” New treatments for prostate cancer and BPH show promise, including novel compounds that target hormone synthesis and response.
29 citations
,
July 2012 in “The Journal of Sexual Medicine” Rats had lasting erectile problems after stopping a certain medication.
January 2020 in “Nihon Yakuri Gakkai nenkai yoshishu” Reducing 5α-reductase activity helps endometrial cells differentiate, aiding pregnancy.
September 2006 in “Aktuelle Urologie” Combination drug therapies are more effective for high-risk BPS patients but have more side effects and costs.
1 citations
,
January 2015 in “Sexual Medicine Reviews” Current treatments for recurrent ischemic priapism are not well-defined and need more research.
20 citations
,
January 2004 in “PubMed” Dutasteride reduces DHT more than finasteride, but both drugs improve BPH symptoms similarly.
53 citations
,
June 1993 in “Proceedings of the National Academy of Sciences of the United States of America” LY191704 is a compound that effectively blocks a specific enzyme involved in hormone conversion and could help treat enlarged prostate and hair loss.
April 2022 in “Reactions Weekly”
June 2018 in “The Journal of Sexual Medicine” Low-intensity shock wave therapy is effective in treating erectile dysfunction in diabetic patients.
May 2024 in “International journal of medicine and psychology.” Ticagrelor works better than clopidogrel in reducing platelet activity in elderly patients with acute coronary syndrome.
15 citations
,
November 2015 in “Pharmacopsychiatry” α-Blockers and 5-ARIs for BPH can cause sexual dysfunction, including erectile and ejaculatory issues.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for treating prostate issues and hair loss without hormonal side effects.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for hair loss and prostate issues without hormonal side effects.
July 2025 in “Saudi Journal of Medicine and Public Health” 5α-reductase inhibitors effectively treat enlarged prostate and hair loss but require careful use due to possible side effects.
5α-reductase inhibitors help treat prostate enlargement and hair loss but may cause side effects, requiring careful use.
January 2021 in “Figshare” Finasteride's molecular properties and active sites were identified using computational methods.
October 2015 in “Prostate Cancer” Finasteride and dutasteride reduce prostate cancer risk, but finasteride may increase higher-grade cancer risk.
3 citations
,
January 2001 in “Cambridge University Press eBooks” Finasteride effectively treats hair loss and enlarged prostate in men, with mild side effects.